Sophie P.
- Country
- France
- Department
- Hematology Department
Research Overview
- Evaluation of Venetoclax and Azacitidine Combination Therapy Versus Placebo and Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome
- Phase II Multicenter Study of RVU120 in Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes Using SEL120 Monohydrochloride
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Tamibarotene and Azacitidine in RARA-positive Higher-risk Myelodysplastic Syndrome
Data & Insights
Has run more than one trial at 73 of 162 partner sites.
Specializations
Myelodysplastic Syndromes (MDS)
This investigator specializes in the treatment of myelodysplastic syndromes, with particular emphasis on both higher-risk and lower-risk disease states. Their research encompasses novel therapeutic approaches for patients with varying risk classifications.
- Higher-risk MDS treatment strategies
- Lower-risk MDS management
- IDH1/IDH2 mutation targeted therapies
Therapeutic Combinations
The investigator focuses on evaluating innovative combination treatments, particularly exploring the potential of venetoclax-based therapies in conjunction with established agents like azacitidine for various myeloid conditions.
- Venetoclax combination studies
- Novel drug combinations
- Treatment optimization strategies
Specialized Treatment Areas
Research interests extend to specific therapeutic challenges including anemia management in MDS and treatment approaches for chronic myelomonocytic leukemia (CMML).
- Anemia interventions
- Post-transplant therapy
- CMML treatment strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.